Professor Roger Daly Related News
First step towards switching off breast cancer and leukaemia
MEDIA RELEASE:
08 Aug 2008
Garvan scientists have identified a way to ‘switch off’ a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia. The molecule, known as Gab2, operates downstream of a major breast cancer oncogene, HER2, the target of the drug Herceptin.
